# Drugs Made In America Acquisition Corp. (DMAAR)

**Exchange:** NASDAQ  
**Price:** $0.10 (-0.99%)

> Drugs Made In America Acquisition Corp. is a special purpose acquisition company (SPAC) organized to identify and merge with one or more businesses in the pharmaceutical sector. Its primary function is to source acquisition opportunities that can establish a comprehensive, domestically-focused drug manufacturing and distribution platform. The company is particularly focused on advancing U.S.-based pharmaceutical production, aiming to reduce dependence on overseas suppliers by investing in advanced manufacturing technologies and supporting the onshoring of critical supply chains. This approach not only aims to enhance the reliability and cost-efficiency of medication supply but also has implications for national security and job creation within the United States. Under the leadership of a seasoned management and advisory team with deep industry experience, Drugs Made In America Acquisition Corp. positions itself at the intersection of healthcare innovation and industrial policy, seeking to address market and strategic needs within the U.S. pharmaceutical landscape.

Financial data not yet available for this company.

Source: [CompaniesByCap](https://companiesbycap.com/company/DMAAR)